Genoa Ventures Promotes Vikram Chaudhery, Ph.D., as Partner


Amy Harris joins the company as vice president of finance as the start-up venture capital firm continues to grow

SAN FRANCISCO, May 16, 2022–(BUSINESS WIRE)–Genoa Ventures, the pioneering venture capital fund that invests where biology and technology converge, today announced the promotion of Vikram Chaudhery, Ph.D., to Partner and the appointment of Amy Harris as Vice President of Finance, adding to the capabilities and depth of the business.

“It’s my passion to build companies and products that transform industries and have the potential to help humanity by integrating technology into biology,” said Dr. Chaudhery. “Genoa has given me an incredible opportunity to expand my reach in this space, providing a platform to work with companies to help them grow and evolve to ultimately create category-changing transformation. I feel so lucky to work with Jenny and the entire Genoa team who share this passion.”

Prior to joining Genoa in 2019, Dr. Chaudhery served as Head of Life Sciences at Lam Research, where he led the global strategy, partnerships/business development and venture capital investment functions for life sciences, focusing on next-generation omics technologies. Under his leadership, investments included Nanostring, Omniome, Antheia and MissionBio. Vikram also led the Life Sciences Tools practice at McKinsey & Co, working with pharmaceutical, diagnostics, medical device and biotech companies to drive operational efficiency and drive new business development. Dr. Chaudhery is co-author of more than a dozen peer-reviewed scientific publications, having obtained his Ph.D. in Electrical Engineering and Biological Systems Engineering from the University of Illinois.

“When I started Genoa Ventures, my mission was to make venture funding available to a class of entrepreneurs who had been largely overlooked by traditional tech and healthcare venture capital firms. Vikram brings unique insights into our investment process and expands our reach into new areas of innovation while also inspiring the trust of his colleagues and the companies he advises,” said Jenny Rooke, Ph.D., Founder and General Manager of Genoa.

Amy Harris joins Genoa Ventures to lead the company’s finance function and fund administration. Amy’s role will bring essential back-office capabilities in-house and enable her to be a resource to portfolio companies by providing strategic financial advice. Prior to joining Genoa, Amy was Vice President of Finance at Village Global and at JAZZ Venture Partners.

“We are also extremely excited to have Amy on board to provide essential operational support internally and expand the ways our team can support our rapidly growing portfolio companies,” said Dr. Rooke.

The new roles of Dr. Chaudhery and Ms. Harris come as Genoa continues to expand the company’s investments in category-defying companies that innovate at the convergence of biology and technology. Each member of Genoa Ventures’ investment team has worked in all areas of biology and technology – as investors, scientists, engineers, inventors, entrepreneurs, operators and advisors. Genoa’s portfolio companies span life science tools, diagnostics, medtech, agribusiness and bioindustrial – verticals where start-ups often exceed the reach and expertise of venture capital traditional health care/life sciences.

For more information about Genoa Ventures, please visit

About Genoa Ventures

Genoa Ventures invests in early-stage companies working in the convergence of biology and technology to accelerate the pace of innovation, transform industries, and solve some of life’s most fundamental challenges. Genoa identifies opportunities early on and focuses its investments and expertise to empower the next big companies that will define their category. The Genoa team has a uniquely chimerical mix of experience ranging from scientific research and discovery to building companies in the life sciences and technology sectors. The team applies this diverse experience to provide expert guidance to its businesses as they evolve and grow. For more information, follow us on LinkedIn, Twitteror online at

See the source version on


Media Contact
Andrea Vuturo, Vuturo Group
[email protected]
847 772 2205


About Author

Comments are closed.